SEATTLE, May 3, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced a poster presentation discussing its Hybrid mRNA Technology™ platform as well as its lead product candidate, PRX-OTC, at the 20th Annual Meeting of the American Society of Gene & Cell Therapy, to be held at the Marriott Wardman Park, May 10-13, 2017 in Washington D.C. PRX-OTC is in development for the treatment of ornithine transcarbamylase deficiency.
- Title of Abstract: Correction of Ornithine Transcarbamylase Deficiency Following Treatment with PhaseRx's Hybrid mRNA Technology™ Delivery System and Safety Evaluation in Rats and Non-Human Primates
Presenter: Mary Prieve, Ph.D.
Session Title: Liver-Based Therapy for Genetic and Metabolic Disease
Room: Exhibit Hall A & B South
Time: Thursday, May 11, 2017 from 5:15 to 7:15 p.m. EST
PhaseRx is a biopharmaceutical company dedicated to developing mRNA products for the treatment of children with inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy (i-ERT). PhaseRx's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of twelve and are characterized by the body's inability to remove ammonia from the blood with potentially devastating consequences for patients. The company's i-ERT approach is enabled by its proprietary Hybrid mRNA Technology™ platform. PhaseRx is headquartered in Seattle. For more information, please visit www.phaserx.com.
Erin S. Cox
Director of Investor Relations
Corporate Communications Contact:
Senior Vice President
Robert H. Uhl
Westwicke Partners, LLC
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/phaserx-to-present-data-at-the-american-society-of-gene--cell-therapy-20th-annual-meeting-300450322.html
SOURCE PhaseRx, Inc.